Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + BEAM in T-cell Lymphoma ASCT
NCT05367856Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in T-cell lymphoma, sponsored by Ruijin Hospital. Primary endpoint: Progression free survival at 2 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT05367856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367856.